Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Report Additional Phase 3 Clinical Trial Data for Peginesatide in Dialysis Patients at the National Kidney Foundation Spring Clinical Meetings

LAS VEGAS & OSAKA, Japan--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”), today announced results of additional analyses from two Phase 3 studies (EMERALD 1 and 2) of the investigational agent, peginesatide (formerly known as Hematide™) in chronic renal failure (CRF) patients on dialysis with anemia. Building on the primary analysis of the EMERALD studies, which showed that once-monthly peginesatide was comparable to epoetin given up to 13 times a month in maintaining hemoglobin (Hb) levels with a generally similar adverse event rate, these data provide additional information on the maintenance of Hb within treatment targets over time (up to 100 weeks), as well as cardiovascular safety results of this once-monthly agent in the dialysis patients studied.1,2 These data, along with a demographic analysis from the dialysis studies, were part of three poster presentations at the National Kidney Foundation’s (NKF) Spring Clinical Meetings in Las Vegas, Nevada.